These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 29156890)

  • 1. Why the results of adjuvant pertuzumab in HER2-positive early breast cancer has been received as a mitigate success?
    Pivot X; Cox DG; Gligorov J
    Chin Clin Oncol; 2018 Feb; 7(1):1. PubMed ID: 29156890
    [No Abstract]   [Full Text] [Related]  

  • 2. Adjuvant pertuzumab improves early breast cancer outcomes.
    Das M
    Lancet Oncol; 2017 Jul; 18(7):e378. PubMed ID: 28625555
    [No Abstract]   [Full Text] [Related]  

  • 3. Contextualizing pertuzumab approval in the treatment of HER2-positive breast cancer patients.
    Cortés J; Ciruelos E; Pérez-García J; Albanell J; García-Estévez L; Ruiz-Borrego M; Espinosa R; Gallegos I; González S; Álvarez I; Llombart A
    Cancer Treat Rev; 2020 Feb; 83():101944. PubMed ID: 31830538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-DM1 in the Neo-Adjuvant Treatment of HER2-Positive Breast Cancer: Impact of the KRISTINE (TRIO-021) Trial.
    Okines AF
    Rev Recent Clin Trials; 2017; 12(3):216-222. PubMed ID: 28552047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Lymph Node-Negative, Early-Stage HER2-Positive Breast Cancer.
    Oguz A; Keskin GS; Colak D; Altundag O; Akcali Z
    J Clin Oncol; 2016 Feb; 34(6):639-40. PubMed ID: 26644534
    [No Abstract]   [Full Text] [Related]  

  • 6. Neoadjuvant Therapy for HER2-positive Breast Cancer.
    Wuerstlein R; Harbeck N
    Rev Recent Clin Trials; 2017; 12(2):81-92. PubMed ID: 28164759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the risk-benefit ratio of adjuvant trastuzumab-based therapy for T1a,bN0M0 HER2-positive breast carcinomas.
    Rodrigues MJ; Albiges-Sauvin L; Wassermann J; Cottu PH
    Ann Oncol; 2011 Nov; 22(11):2530. PubMed ID: 21700734
    [No Abstract]   [Full Text] [Related]  

  • 8. Systemic therapy for HER2-positive early-stage breast cancer.
    Mathew A; Romond EH
    Curr Probl Cancer; 2016; 40(2-4):106-116. PubMed ID: 27816189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pertuzumab and its accelerated approval: evolving treatment paradigms and new challenges in the management of HER2-positive breast cancer.
    O'Sullivan CC; Connolly RM
    Oncology (Williston Park); 2014 Mar; 28(3):186-94, 196. PubMed ID: 24855725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
    Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
    J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exceptional Response to Pembrolizumab and Trastuzumab in a Heavily Pretreated Patient With HER2-Positive TMB-H and MSI-H Metastatic Breast Cancer.
    Li A; Goodyear S; Fuss C; Mitri Z
    JCO Precis Oncol; 2021 Nov; 5():904-909. PubMed ID: 34994619
    [No Abstract]   [Full Text] [Related]  

  • 12. Is trastuzumab active following conventional adjuvant chemotherapy in HER2-positive early breast cancer?
    Seidman AD
    Nat Clin Pract Oncol; 2006 Apr; 3(4):178-9. PubMed ID: 16596138
    [No Abstract]   [Full Text] [Related]  

  • 13. Pertuzumab in HER2-positive breast cancer.
    Sendur MA; Aksoy S; Altundag K
    Curr Med Res Opin; 2012 Oct; 28(10):1709-16. PubMed ID: 22953713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.
    Scheuer W; Friess T; Burtscher H; Bossenmaier B; Endl J; Hasmann M
    Cancer Res; 2009 Dec; 69(24):9330-6. PubMed ID: 19934333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse Mucocutaneous Reaction to Pertuzumab in a Patient with HER2-Positive Metastatic Breast Cancer.
    Kowalczyk L; Singer CF; Staudigl C; Weber M; Farr A
    Breast J; 2017 May; 23(3):352-353. PubMed ID: 27563723
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
    Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
    Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [T-DM1 and pertuzumab: emerging anti-HER2 therapeutics].
    Noguchi E; Shimizu C
    Gan To Kagaku Ryoho; 2013 Jan; 40(1):10-4. PubMed ID: 23306913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reply to A. Oguz et al.
    O'Sullivan CC; Holmes E; Campbell C; Bradbury I; Zujewski JA; Gelber RD
    J Clin Oncol; 2016 Feb; 34(6):640-1. PubMed ID: 26644531
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.
    De Mattos-Arruda L; Cortes J
    Adv Ther; 2013 Jul; 30(7):645-58. PubMed ID: 23881722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual HER2 Blockade Helps Prevent Breast Cancer Return.
    Cancer Discov; 2017 Aug; 7(8):790. PubMed ID: 28588061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.